This lawsuit is for anyone who acquired securities in Nabriva Therapeutics plc (NASDAQ: NBRV) from November 1, 2018 through April 30, 2019.
The lawsuit alleges that the Company and certain of its executives violated federal law. Specifically, the lawsuit alleges that, in the Prospectus to the Company's July 24, 2018 Secondary Offering, and throughout the time period mentioned above, the Company misled investors regarding its financial condition. More specifically, the lawsuit alleges that the Company misled investors by telling them that the Company had controls in place to safely manufacture ONTEPO™ (fosfomycin) when the Company did not have such controls in place.
On April 30, 2019, the Company revealed that it had received a Complete Response Letter from the FDA for its New Drug Application for ONTEPO™ (fosfomycin), a drug used to treat complicated urinary tract infections, denying approval because the Company had failed to address certain “issues related to facility inspections and manufacturing deficiencies at one of Nabriva’s contract manufacturers.” On this news, the price of the Company's stock dropped precipitously on unusually heavy trading volume. Currently, the stock trades for less than it did at the Company's Secondary Offering.
The Law Offices of Howard G. Smith seeks to recover damages on behalf of class members. If you acquired securities in Nabriva Therapeutics plc (NASDAQ: NBRV) from November 1, 2018 through April 30, 2019 you may join the lawsuit by submitting your information online, or you may call the Law Offices of Howard G. Smith and speak to Mr. Smith directly to learn how he can protect your rights.
Join the Class Action
First Name: *
Last Name: *
If Representing an Institution, Name of Institution:
If Representing an Institution, Position at Institution:
Mailing Address: *
Phone #: *
I, the Plaintiff, certify that:
1. I have reviewed the Complaint and authorized its filing.
2. Plaintiff did not purchase the security that is the subject of this
action, at the direction of plaintiff's counsel or in order to
participate in any private action arising under this title.
3. I am willing to serve as a representative party on behalf of a class
and will testify at deposition and trial, if necessary.
4. My transactions in the securities, which are the subject of this
action, during the Class Period set forth in the Complaint are as
5. I have not served as a representative party on behalf of a class
under the federal security laws during the last three years, except
if detailed below.
6. I will not accept any payment for serving as a representative party,
except to receive my pro rata share of any recovery or as ordered
or approved by the court including the award to a representative
plaintiff of reasonable costs and expenses (including lost wages)
directly relating to the representation of the class.
agreement and retain the Law Offices of Howard G. Smith and its associates to proceed on Plaintiff's behalf, on a contingent fee basis. If I am executing this agreement on behalf of an institution, I further certify that I am authorized to execute this agreement on behalf of the institution.